Gulf International Bank UK Ltd Has $2.05 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Gulf International Bank UK Ltd reduced its position in DexCom, Inc. (NASDAQ:DXCM) by 4.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 30,638 shares of the medical device company’s stock after selling 1,437 shares during the period. Gulf International Bank UK Ltd’s holdings in DexCom were worth $2,053,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. bought a new position in DexCom during the second quarter worth $25,000. Sachetta LLC lifted its holdings in DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the last quarter. Crewe Advisors LLC bought a new stake in DexCom in the 1st quarter valued at $29,000. Riverview Trust Co grew its holdings in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares in the last quarter. Finally, DT Investment Partners LLC increased its position in DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after buying an additional 315 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus boosted their target price on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd. UBS Group decreased their target price on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Raymond James lowered their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Leerink Partners cut their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, Oppenheimer lowered their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Trading Down 0.6 %

Shares of DXCM stock opened at $68.61 on Thursday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $26.80 billion, a P/E ratio of 41.08, a P/E/G ratio of 2.16 and a beta of 1.17. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The stock’s fifty day simple moving average is $69.66 and its 200 day simple moving average is $94.30.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.